Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06703138

Role of Diffusion MRI in Differentiation of Various Bone Marrow Lesions

Bone marrow lesions are common, and imaging findings are associated with various aetiologies, as compared to conventional radiography and computed tomography (CT), MRI is a better non-invasive imaging modality to evaluate vertebral bone marrow, due to better soft-tissue contrast, so the aim of our study is the use of MRI diffusion in differentiating various vertebral bone marrow pathological lesions.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Observational

About this study

Bone marrow lesions are common, and imaging findings are associated with various aetiologies, such as degenerative, infectious, traumatic, malignant, metabolic, and haematopoietic .

As compared to conventional radiography and computed tomography (CT), MRI is a better non-invasive imaging modality to evaluate vertebral bone marrow, due to better soft-tissue contrast as well as being non-ionising in nature .

Although conventional MRI is essential for anatomical visualization and lesion detection in bone marrow pathologies ,but it often insufficient in distinguishing different vertebral bone marrow lesions, due to overlapping imaging features and often due to coexistence of bone marrow oedema that can be caused by fractures, infection, and bone marrow hyperplasia, thus reducing the specificity of conventional sequences .

MRI diffusion provides complementary information about tissue microstructure and cellular .it exploits the translational mobility of water molecules to obtain information on the microscopic behaviour of the tissues.

On the other hand, apparent diffusion coefficient (ADC) values provide quantitative measure of Brownian movement with low ADC values implying restricted diffusion and high values being a measure of free diffusion.

Therefore, DWI provides both qualitative and quantitative functional information concerning the microscopic movements of water at the cellular level. The benefits of DWI comprise a small scanning period that allows it to be easily included in the routine imaging protocols .

For example, In healthy bone marrow, water diffusion is relatively unrestricted due to its cellularity and vascularity, while pathologies such as metastatic disease or myelofibrosis typically exhibit restricted diffusion.

Diffusion MRI can also distinguish bone marrow edema like acute injury or inflammation, from infiltrative diseases such as multiple myeloma. Edema typically shows higher ADC values due to the increased water content, whereas infiltrative diseases reduce diffusion, resulting in lower ADC values.

These examples illustrate how MRI diffusion can differentiate various vertebral bone marrow pathological lesions.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All adult patients with vertebral lesions Clinically suspected or diagnosed by other modalities as X-ray or CT were included in the study.

Exclusion criteria

  • Patients with metallic prosthesis which are not MRI compatible .
  • patients with previous Vertebral surgery.
  • patients with Vertebral Congenital anomalies
  • Patients refused the examination.
  • Patients who suffer from claustrophobia

Treatment and study plan

Primary outcomes

  1. Evaluation of the efficacy of MRI diffusion in differentiation between Various Vertebral bone marrow pathological lesions. .

    Time frame: Baseline

    Primary (main):

    Establishing correlations between DWI findings and laboratory, clinical or histopathological results.

Study contacts

Contact information is provided by the study sponsor or research team.

Zeinab H. Mahmoud

CONTACT

[email protected]

+201553673982

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Role of MRI Diffusion in Differentiation Between Various Vertebral Bone Marrow Pathological Lesions. .

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Nov 25, 2024
Registry last updated
Nov 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.